XOMAP XOMA Royalty Corp

Nasdaq Pharmaceutical Preparations NV CIK: 0000791908
AI RATING
HOLD
68% Confidence

Investment Thesis

Exceptional revenue growth of 403.9% YoY and industry-leading net margins of 60.8% are undermined by severe cash flow deterioration—negative free cash flow of -96.1M and interest coverage below 1x indicate the company cannot cover debt servicing from operations, raising questions about earnings quality and financial sustainability despite reported profitability.

Strengths

  • + Exceptional YoY revenue growth of 403.9% with net income up 71.3%
  • + Outstanding profitability metrics: 60.8% net margin, 37.8% ROE, and 21.8% operating margin
  • + Strong balance sheet liquidity with 3.37x current ratio and $82.9M in cash equivalents

Risks

  • ! Severely negative free cash flow of -96.1M despite profitability; company burns cash operationally
  • ! Interest coverage of 0.9x indicates operating income cannot cover interest expenses; financial distress signal
  • ! Disconnect between reported $31.7M net income and only $2.9M operating cash flow; significant earnings quality concerns
  • ! Capital expenditure of $99M on $52.1M revenue is unsustainable and dependent on external financing or cash depletion

Key Metrics to Watch

Financial Metrics

Revenue
52.1M
Net Income
31.7M
EPS (Diluted)
$1.46
Free Cash Flow
-96.1M
Total Assets
272.7M
Cash
82.9M

Profitability Ratios

Gross Margin N/A
Operating Margin 21.8%
Net Margin 60.8%
ROE 37.8%
ROA 11.6%
FCF Margin -184.3%

Balance Sheet & Liquidity

Current Ratio
3.37x
Quick Ratio
3.37x
Debt/Equity
1.15x
Debt/Assets
61.9%
Interest Coverage
0.87x
Long-term Debt
96.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-19T14:39:20.154254 | Data as of: 2025-12-31 | Powered by Claude AI